Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2427]

Screen-detectable cancers account for majority of early-onset cancer cases...

Prof Aldenise Ewing - The Ohio State University, Colombus, USA

Screen-detectable cancers account for majority of early-onset cancer cases under age 50 ( Prof Aldenise Ewing - The Ohio State University, Colombus, USA )

Oral molecular glue degrader with or without spartalizumab shows immune...

Dr Elena Garralda - Vall d’Hebron University Hospital, Barcelona, Spain

Oral molecular glue degrader with or without spartalizumab shows immune activation and tumour control in solid tumours ( Dr Elena Garralda - Vall d’Hebron University Hospital, Barcelona, Spain )

Daraxonrasib plus chemotherapy shows promising first-line activity in RAS...

Dr Brian Wolpin - Dana-Farber Cancer Institute, Boston, USA

Daraxonrasib plus chemotherapy shows promising first-line activity in RAS-mutant metastatic pancreatic cancer ( Dr Brian Wolpin - Dana-Farber Cancer Institute, Boston, USA )

Oncolytic adenovirus VCN-01 plus chemo shows promising survival benefit in...

Dr Manuel Hidalgo - NYU Langone Health, New York, USA

Oncolytic adenovirus VCN-01 plus chemo shows promising survival benefit in metastatic pancreatic cancer ( Dr Manuel Hidalgo - NYU Langone Health, New York, USA )

ctDNA predicts early treatment response in HPV-associated anal cancer

Dr Phebe Mawuena Afi Havor - Moffitt Cancer Center, Tampa, USA

ctDNA predicts early treatment response in HPV-associated anal cancer ( Dr Phebe Mawuena Afi Havor - Moffitt Cancer Center, Tampa, USA )

Rilvegostomig clears ctDNA and delays recurrence in high-risk head and neck...

Dr Enrique Sanz-Garcia - UHN Princess Margaret Cancer Centre, Toronto, Canada

Rilvegostomig clears ctDNA and delays recurrence in high-risk head and neck cancer ( Dr Enrique Sanz-Garcia - UHN Princess Margaret Cancer Centre, Toronto, Canada )

Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC

Dr Miranda Gogishvili - High Technology Medical Centre, Tbilisi, Georgia

Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC ( Dr Miranda Gogishvili - High Technology Medical Centre, Tbilisi, Georgia )

Sevabertinib shows manageable diarrhoea without impacting efficacy in HER2...

Prof Nicolas Girard - Institut Curie, Paris, France

Sevabertinib shows manageable diarrhoea without impacting efficacy in HER2-mutant lung cancer ( Prof Nicolas Girard - Institut Curie, Paris, France )

Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant...

Prof Nicolas Girard - Institut Curie, Paris, France

Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant advanced lung cancer ( Prof Nicolas Girard - Institut Curie, Paris, France )

EAU 2026: Updates in NMIBC

Dr Francesco Soria, Prof Jonathan Aning, Dr Antoni Vilaseca and Prof Alexandra...

EAU 2026: Updates in NMIBC ( Dr Francesco Soria, Prof Jonathan Aning, Dr Antoni Vilaseca and Prof Alexandra Masson-Lecomte )

Microplastics found at higher levels in prostate cancer tissue compared to...

Dr Stacy Loeb - NYU Langone Health, New York, NY

Microplastics found at higher levels in prostate cancer tissue compared to benign tissue ( Dr Stacy Loeb - NYU Langone Health, New York, NY )

Durvalumab plus tremelimumab temporarily reduces QoL in resected renal cell...

Dr Sophie Merrick - University College London, London, UK

Durvalumab plus tremelimumab temporarily reduces QoL in resected renal cell carcinoma patients ( Dr Sophie Merrick - University College London, London, UK )

More from ecancer